NHS England -
The aim of the new Cancer Drugs Fund (CDF) is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the NHS in the future. The original CDF was established in 2011 to fund cancer drugs in England that are not currently approved by NICE and will run until April 2016. The CDF has helped more than 72,000 cancer patients in England access drugs not routinely funded, but it is now widely acknowledged that a new system is needed. A proposal has been issued for public consultation which outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund - with clear criteria for entry and exit. This is in line with the recommendation of the recently published independent Cancer Taskforce report, which proposed that the new CDF should operate with NHS England and NICE. The closing date for comments is 11 February 2016.